These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 32421446)

  • 41. [Management of adverse effects of targeted therapy toxicities in oncology].
    Coquan E; Henri P; de Raucourt S; Lireux B; Lamy E; Delcambre C; Sevin E; Dutriaux C; Bouhier-Leporrier K; Gervais R; Joly F
    Rev Prat; 2012 Jan; 62(1):17-25. PubMed ID: 22335060
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors.
    Vigarios E; Epstein JB; Sibaud V
    Support Care Cancer; 2017 May; 25(5):1713-1739. PubMed ID: 28224235
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Management of Dermatologic Toxicities Related to Immune Checkpoint Inhibitors].
    Si X; He C; Zhang L; Liu X; Li Y; Wang H; Guo X; Zhou J; Duan L; Zhang L
    Zhongguo Fei Ai Za Zhi; 2019 Oct; 22(10):639-644. PubMed ID: 31650946
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Supportive therapy and management of side effects in dermato-oncology].
    von Dücker L; Hüning S; Kähler K; Terheyden P; Nashan DRT
    Hautarzt; 2019 Dec; 70(12):975-988. PubMed ID: 31720719
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Managing cutaneous toxicities of targeted therapies].
    Kiyohara Y
    Gan To Kagaku Ryoho; 2012 Nov; 39(11):1597-602. PubMed ID: 23152009
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Non-rash dermatologic adverse events related to targeted therapies.
    Bryce J; Boers-Doets CB
    Semin Oncol Nurs; 2014 Aug; 30(3):155-68. PubMed ID: 25085027
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tumor control versus adverse events with targeted anticancer therapies.
    Keefe DM; Bateman EH
    Nat Rev Clin Oncol; 2011 Dec; 9(2):98-109. PubMed ID: 22182972
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Radiological assessment of response and adverse events associated with novel systemic oncological therapies.
    Veerasuri S; Little D; De Paepe KN; Andreou A; Bowen R; Beresford M; Tillett T; Gangadhara S; Loughborough WW
    Clin Radiol; 2021 Apr; 76(4):247-261. PubMed ID: 33423761
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Economic burden of dermatologic adverse events induced by molecularly targeted cancer agents.
    Borovicka JH; Calahan C; Gandhi M; Abraham TS; Kwasny MJ; Haley AC; West DP; Lacouture ME
    Arch Dermatol; 2011 Dec; 147(12):1403-9. PubMed ID: 22184762
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel.
    Cury-Martins J; Eris APM; Abdalla CMZ; Silva GB; Moura VPT; Sanches JA
    An Bras Dermatol; 2020; 95(2):221-237. PubMed ID: 32165025
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cutaneous Adverse Reactions of Anticancer Agents.
    Kaul S; Kaffenberger BH; Choi JN; Kwatra SG
    Dermatol Clin; 2019 Oct; 37(4):555-568. PubMed ID: 31466595
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dermatologic adverse events of checkpoint inhibitors: what an oncologist should know.
    Habre M; Habre SB; Kourie HR
    Immunotherapy; 2016 Dec; 8(12):1437-1446. PubMed ID: 28000535
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Systematic Review of adverse events reporting in clinical trials leading to approval of targeted therapy and immunotherapy.
    Bossi P; Botta L; Bironzo P; Sonetto C; Musettini G; Sbrana A; Di Giannantonio V; Locati LD; Di Maio M; Antonuzzo A
    Future Oncol; 2019 Jul; 15(21):2543-2553. PubMed ID: 31240949
    [No Abstract]   [Full Text] [Related]  

  • 54. Cutaneous adverse events in patients receiving anticancer therapy in a tertiary hospital setting: the old and the new.
    Suh HJ; Flórez Á; Sacristán V; Rodríguez Martinez Á; Fernández F; Vilanova-Trillo L; Constenla M; Pereiro M
    Int J Dermatol; 2021 Feb; 60(2):208-216. PubMed ID: 33502780
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Skin Manifestations of Targeted Antineoplastic Therapy.
    Sanmartín O
    Curr Probl Dermatol; 2018; 53():93-104. PubMed ID: 29131041
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Brain metastases and treatment: multiplying cognitive toxicities.
    Nassif EF; Arsène-Henry A; Kirova YM
    Expert Rev Anticancer Ther; 2019 Apr; 19(4):327-341. PubMed ID: 30755047
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cutaneous reactions related to systemic immunomodulators and targeted therapeutics.
    Hammond-Thelin LA
    Dermatol Clin; 2008 Jan; 26(1):121-59, ix. PubMed ID: 18023775
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neuro-ophthalmic side effects of molecularly targeted cancer drugs.
    Bhatti MT; Salama AKS
    Eye (Lond); 2018 Feb; 32(2):287-301. PubMed ID: 29052609
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cutaneous Reactions to Targeted Therapy.
    Lee JJ; Kroshinsky D; Hoang MP
    Am J Dermatopathol; 2017 Feb; 39(2):67-82. PubMed ID: 28134724
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dermatologic toxicities of targeted anticancer therapies.
    Balagula Y; Lacouture ME; Cotliar JA
    J Support Oncol; 2010; 8(4):149-61. PubMed ID: 20822032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.